In addition , 31 patients had lymph node metastasis and 38 patients did not. esophageal mucosa (P <0. 001). The expression of HDAC2 was not associated with the age or gender of patients (P> 0. 05), but was closely associated with the histological grade, invasion depth, tumor-node-metastasis stage and lymph node metastasis, respectively (all P <0. 001). HDAC2 small interfering RNA effectively downregulated the expression of HDAC2 protein in ESCC EC9706 cells. Downregulation of HDAC2 expression evidently inhibited cell proliferation, arrested cell cycle at the G0/G1 phase Rabbit polyclonal to ZNF238 and induced cell apoptosis in ESCC EC9706 cells, coupled with increased expression of p21 and Bax proteins and decreased expression of cyclin D1 and Bcl-2 proteins. Overall, the present findings suggest that HDAC2 may play an important role in the development and progression of ESCC and be considered as a book molecular target for the treatment of ESCC. Keywords: histone deacetylase 2, esophageal squamous cell carcinoma, cell proliferation, cell cycle, cell apoptosis == Introduction == Esophageal cancer (EC) is a gastrointestinal cancer that is the eighth most common cancer and the sixth most lethal cancer globally (14). The incidence of EC, particularly esophageal squamous cell carcinoma (ESCC), which is the most prevalent histological type of EC, exhibits a significant geographical distribution, with areas of large incidence located mainly in China, South Asia, East Africa and South Africa (3, 5). Currently, the prognosis of patients with ESCC is quite poor, with a 5-year relative survival rate of <10% (6). Since early-onset ESCC is asymptomatic, the majority of Importazole diagnosed ESCCs are already in a late stage of disease. It is therefore imperative to identify new molecular diagnostic markers for early intervention in ESCC. Deacetylases are frequently dysregulated in numerous tumors (7, 8), Histone deacetylase 2 (HDAC2), an important member of type I histone deacetylases, plays a crucial role in tumor onset and development (8, 9). Increasing evidence has revealed that HDAC2 is often overexpressed in various types of tumors (1015). In addition , the ablation of HDAC2 markedly inhibits tumor growth and induces apoptosis (13, 14, 16), suggesting HDAC2 functions as oncogene in these tumors. Most importantly, monitoring HDAC2 expression during treatment can work as a marker for the efficacy of HDAC inhibitors (HDACis), and thus the HDAC2 level represents an independent prognostic marker in the clinic (17, 18). However , at present, the role of HDAC2 in the development and progression of ESCC remains to be elucidated. Therefore , in the current study, HDAC2 expression in ESCC cells was determined by immunohistochemistry. EC9706 cells were also transfected with liposome-mediated HDAC2 small interfering (si)RNA, followed by cell proliferation, cell cycle and cell-apoptosis assays, and the underlying molecular mechanism was analyzed. Overall, the present findings indicated that HDAC2 may be a book molecular target for the therapy of ESCC. == Components and methods == == == == Tissue samples == To get the cells samples, 69 patients with ESCC were enrolled from Anyang Tumor Hospital (Anyang, China), a place with a large incidence of esophageal cancer (19). In total, Importazole 45 atypical hyperplasia cells specimens within 3 cm of the tumor and an additional 69 samples of normal cells were used as regulates. Of the 69 patients with esophageal cancer, 41 were male and 28 were female. In total, 27 patients were 60 years old, and 42 patients were > 60 years aged. Standards of histological grading were as follows: Grade I, highly differentiated squamous cell carcinoma, with keratin pearls and intercellular bridges; grade II, rare intercellular bridges that are not because evident as in grade I, and the cells of the special type of medium; and grade III, poorly differentiated squamous cell carcinoma, cell dispersion distribution, large and abnormal nucleus, and absence of intercelllar bridges. Patients showed the subsequent histology: Grade I, 19 patients; grade II, 27 patients; and grade III, 23 patients. Additionally , 22 patients exhibited shallow invasion to the submucosa or superficial-layer muscle, and 47 patients exhibited deep invasion to deep-layer muscle or fibrous membrane. Based Importazole on the Union for International Cancer Control 1997 tumor-node-metastasis (TNM) staging criteria, 33 patients were diagnosed with stage III disease and 36 patients were diagnosed with stage IIIIV disease. In addition , 31 patients had lymph node metastasis and 38 patients did not. Almost all patients had no history of chemotherapy or radiotherapy. All the aforementioned specimens were fixed in 4% paraformaldehyde, conventionally dehydrated, embedded in paraffin, serially sectioned (46 m thick), and stained by hematoxylin-eosin (HE) staining (Beijing Zhongshan Fantastic Bridge Biotechnology Co., Ltd., Beijing, China). The classification Importazole of regular, atypical hyperplasia and tumor tissues was confirmed by HE staining. The present study was approved by the Ethical Review Committee of the 1st Affiliated Hospital of Zhengzhou University (Zhengzhou, China) and written knowledgeable consent was obtained from almost all participants. == Evaluation of immunohistochemistry and staining == Immunohistochemistry was performed because previously explained (20). Briefly, streptavidin-peroxidase immunohistochemistry (Beijing Zhongshan Golden Bridge Biotechnology Co.,.